Welcome to our dedicated page for Dupont De Nemours SEC filings (Ticker: DD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DuPont de Nemours, Inc. (NYSE: DD) SEC filings page provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports when available, and exhibits that describe material agreements, capital structure changes and significant portfolio transactions.
DuPont’s recent 8-K filings illustrate how its SEC documents can inform investors about major corporate events. In 2025, DuPont filed multiple 8-Ks detailing the separation of its electronics business into Qnity Electronics, Inc., including the Separation and Distribution Agreement, Tax Matters Agreement, Employee Matters Agreement, Intellectual Property Cross-License Agreement, Transition Services Agreements and a Legacy Liabilities Assignment Agreement. Another 8-K furnishes unaudited pro forma consolidated financial information reflecting DuPont’s post-separation structure.
Filings also describe the planned divestiture of DuPont’s aramids business, including Kevlar and Nomex, through a Transaction Agreement with entities affiliated with Arclin. Additional 8-Ks outline DuPont’s debt and capital markets activities, such as exchange offers for senior notes, supplemental indentures, issuance of new notes, special mandatory redemption provisions, consent solicitations and tender offers for portions of its long-dated notes. These documents provide detailed terms of DuPont’s obligations and capital structure adjustments.
Investors can review DuPont’s 8-K dated November 6, 2025 for quarterly financial results and segment information, including the IndustrialsCo and ElectronicsCo segments prior to the Qnity separation. Other filings report on board and executive changes, as well as the determination of percentages used to calculate Minimum EBITDA thresholds under legacy agreements following the Qnity spin-off.
On Stock Titan, DuPont filings are updated as they are released to EDGAR, and AI-powered summaries can help explain the key points in complex documents such as transaction agreements, supplemental indentures and pro forma financial statements. Users can use this page to locate DuPont’s 10-K and 10-Q reports when filed, as well as Form 8-K disclosures that highlight material events, enabling a deeper understanding of the company’s evolving portfolio, governance and financial commitments.
DuPont de Nemours, Inc. filed an initial SEC Form 3 reporting beneficial ownership in Qnity Electronics, Inc. (Q). The filing dated 09/30/2025 shows DuPont de Nemours holds 100 shares of common stock as direct ownership. The form indicates the reporting person is a director of the issuer and the filing was signed by Erik T. Hoover, Senior Vice President and General Counsel.
Steven P. Larrabee, SVP & CIO of DuPont de Nemours (DD), reported a mix of option exercises, open-market purchases and stock sales on 09/15/2025. He exercised 25,633 options at an effective exercise price of $66.06 (options vested) and 13,575 options at $53.50. Following exercises and trades, he purchased shares via market transactions totaling 39,208 and 4,000 shares were sold at weighted prices around $77.18 and $76.98, respectively, producing a weighted average sales price of $77.18235. His direct beneficial ownership after these transactions is reported as 38,585.1905 shares, plus 147.2117 shares held indirectly in a retirement savings plan.
DuPont de Nemours, Inc. reported that it has amended its previously announced exchange offers for its outstanding 4.725% Notes due 2028 in the principal amount of $2,250,000,000, 5.319% Notes due 2038 in the amount of $1,000,000,000 and 5.419% Notes due 2048 in the amount of $2,150,000,000.
The company is offering to exchange these existing notes for new notes issued by DuPont and is concurrently conducting consent solicitations from eligible holders of each series to adopt amendments to the relevant indentures. The amended terms are described in a confidential offering memorandum and a related supplement, with additional details contained in a press release attached as an exhibit.
DuPont de Nemours insider activity: Steven P. Larrabee, Senior Vice President & Chief Information Officer, reported option exercise and sales in early September 2025. On 09/04/2025 he exercised 25,000 stock options with an exercise price of $66.06 (code M), resulting in acquisition of 25,000 shares. He sold 25,000 shares on 09/04/2025 at $76.50 and sold an additional 6,000 shares on 09/05/2025 at $78.00. After these transactions he beneficially owned 42,585.1905 shares directly and 147.2117 shares indirectly through the Retirement Savings Plan. The filing notes dividend reinvestment contributed to the reported holdings and that the exercised options were fully exercisable as of 12/31/2021.
Form 144 notice for DuPont de Nemours, Inc. (DD) reports a proposed sale of 92,248 shares of Common stock through Merrill Lynch at 3455 Peachtree Road NE, Atlanta, GA, with an aggregate market value of $7,525,332.00. The filing lists the approximate date of sale as 09/04/2025 and the securities exchange as the NYSE.
The table of acquisition history shows most shares were received as compensatory stock awards from DuPont de Nemours, Inc., including an exercise of stock awards on 09/04/2025 (recorded as 82,248 shares) and multiple vesting events in 2022–2023 (1,865; 5,726; 420; 1,989). The filer certifies they are unaware of undisclosed material adverse information in the issuer.
Insider purchase via dividend reinvestment: Director Frederick M. Lowery acquired 503.7702 shares of DuPont de Nemours, Inc. (DD) on 08/29/2025 at a reported price of $76.92 per share, increasing his direct beneficial ownership to 33,270.0198 shares. The filing notes the acquisition includes shares purchased through a dividend reinvestment program. The Form 4 was signed by Peter W. Hennessey by power of attorney on 09/03/2025.
Cutler Alexander M, identified as a Director of DuPont de Nemours, Inc. (Ticker: DD), reported a purchase of 650.026 shares of DuPont common stock on 08/29/2025 at a price of $76.92 per share. The filing states the acquisition includes shares received through dividend reinvestment.
After this transaction, Mr. Cutler is reported to beneficially own 73,879.0062 shares in a direct ownership form. The Form 4 was signed by power of attorney on 09/03/2025 by Peter W. Hennessey.
Terrence R. Curtin, a director of DuPont de Nemours, Inc. (DD), reported an open-market acquisition on 08/29/2025. The Form 4 shows he acquired 422.5169 shares of DuPont common stock at a price of $76.92 per share, with the filing noting the acquisition includes shares received through dividend reinvestment. After the transaction, Mr. Curtin beneficially owned 30,966.5213 shares in total, including 7,500 shares held indirectly through family trusts.
The Form 4 was signed by Peter W. Hennessey by power of attorney on 09/03/2025. The filing lists Mr. Curtin's address in Wilmington, DE, and identifies his relationship to the issuer as a director.
Amy G. Brady, a director of DuPont de Nemours, Inc. (DD), reported a non-derivative purchase of common stock on 08/29/2025. The Form 4 shows an acquisition of 105.6292 shares at a price of $76.92 per share, bringing her total reported beneficial ownership to 19,274.5372 shares, held directly. The filing includes a disclosure that the total includes shares acquired through dividend reinvestment. The filing was submitted with a signature dated 09/03/2025 by Peter W. Hennessey by power of attorney.
DuPont announced a definitive agreement to sell its Aramids business (Kevlar4 and Nomex4) to Arclin for an enterprise value of approximately $1.8 billion. Under the Transaction Agreement, DuPont will receive roughly $1.2 billion in pre-tax cash at closing (subject to customary adjustments), a $300 million note receivable, and a non-controlling common equity stake in the combined Arclin business currently valued at $325 million, expected to represent about a 17.5% ownership at closing. The agreement is conditioned on customary closing requirements, including regulatory approvals in multiple non-U.S. jurisdictions and satisfactory representations, warranties and performance by the parties.